• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

175414-77-4 (Voreloxin)

1

Identification

Voreloxin Voreloxin
Name Voreloxin
Formula C18H19N5O4S
MW 401.44
CAS No. 175414-77-4
EINECS
Smiles O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[[email protected]](OC)[[email protected]@H](NC)C4)=N3)C1=O)O
Synonyms SNS-595; Vosaroxin; AG 7352; 7-((3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
InChI InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
2

Introduction

Voreloxin(SNS-595; AG 7352) is a small molecule and a naphthyridine analogue with antineoplastic activity; inhibitor of Topo II. IC50 Value: Target: Topoisomerase II Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication.

Background Information

Voreloxin is an anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, causing double-strand breaks in DNA, irreversible G2 arrest, and rapid onset of apoptosis.Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. It evades common resistance pathways of p53 and P-glycoprotein (P- gp) and does not appear to generate significant reactive oxygen species (ROS) associated with these agents. ......by AbMole BioScience
Voreloxin is a small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication ......by AdooQ BioScience, LLC
Description ......by Apexbio Technology LLC
Voreloxin(SNS-595; AG 7352) is a small molecule and a naphthyridine analogue with antineoplastic activity; inhibitor of Topo II. ......by BOC Sciences
Voreloxin is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis. ......by MedChemexpress Co., Ltd.
Voreloxin, also known as SNS-595 or Vosaroxin, is a s mall molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, reducing the risk of cardiotoxicity. ......by MedKoo Biosciences, Inc.
Vosaroxin is a small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. ......by MedKoo Biosciences, Inc.
A first-in-class anticancer quinolone derivative that intercalates DNA and inhibits Topoisomerase II; exhibits proliferation inhibition of AML cell lines MV4-11 and HL-60 with IC50 of 95 nM and 884 nM, respectively.Chemotherapeutic AgentsPhase 3 Clinical ......by ProbeChem
Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2. ......by Target Molecule Corp.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000024260

Storage condition

Solubility

DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Voreloxin Sunesis Pharmaceuticals Inc Acute myelogenous leukemia 2010/10/31 2014/6/1 Phase 3 Clinical
Voreloxin Sunesis Pharmaceuticals Inc Metastatic non small cell lung cancer 2005/11/30 2007/4/30 Phase 2 Clinical
Voreloxin Sunesis Pharmaceuticals Inc Small-cell lung cancer 2006/2/28 2007/8/31 Phase 2 Clinical
Voreloxin Sunesis Pharmaceuticals Inc Ovary tumor 2006/11/30 2010/10/31 Phase 2 Clinical
Voreloxin Sunesis Pharmaceuticals Inc Myelodysplastic syndrome 2008/4/30 2011/5/31 Phase 2 Clinical
Voreloxin Sunesis Pharmaceuticals Inc Acute myelogenous leukemia 2008/4/30 2011/5/31 Phase 2 Clinical
Voreloxin - Phase 3
7

Safety Data of Voreloxin

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AbMole BioScience USA
AdooQ BioScience, LLC USA
Apexbio Technology LLC USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD276();10mg/USD420() USA
MedChemexpress Co., Ltd. 5mg/USD276();10mg/USD420() USA
MedKoo Biosciences, Inc. USA
MedKoo Biosciences, Inc. USA
ProbeChem
Selleck Chemicals LLC USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD276();10mg/USD420() China
Target Molecule Corp. 5mg/USD218() USA
10

Related Products

Other Forms of 175414-77-4

Name CAS No Formula MW
Voreloxin (Hydrochloride) 175519-16-1 C18H20ClN5O4S 437.9

Recommended Compounds in Topoisomerase

Name CAS No Formula MW
Pirarubicin (Hydrochloride) 95343-20-7 C32H38ClNO12 664.1
Exatecan (Mesylate) 169869-90-3 C25H26FN3O7S 531.55
Flumequine 42835-25-6 C14H12FNO3 261.25
Nemorubicin 108852-90-0 C32H37NO13 643.64
Amsacrine (hydrochloride) 54301-15-4 C21H20ClN3O3S 429.92
Ellipticine 519-23-3 C17H14N2 246.31
DOXO-EMCH 151038-96-9 C37H42N4O13 750.75
Topotecan (Hydrochloride) 119413-54-6 C23H24ClN3O5 457.91
Topotecan 123948-87-8 C23H23N3O5 421.45
Tirapazamine 27314-97-2 C7H6N4O2 178.15
Teniposide 29767-20-2 C32H32O13S 656.65
TAS-103 174634-08-3 C20H19N3O2 333.38
TAS-103 (dihydrochloride) 174634-09-4 C20H21Cl2N3O2 406.31
Pixantrone (dimaleate) 144675-97-8 C21H23N5O6 441.44
Pixantrone 144510-96-3 C17H19N5O2 325.37
Pirarubicin 72496-41-4 C32H37NO12 627.64
SN-38 86639-52-3 C22H20N2O5 392.4
Irinotecan (hydrochloride) 100286-90-6 C33H39ClN4O6 623.14
Exatecan 171335-80-1 C24H22FN3O4 435.45
Etoposide 33419-42-0 C29H32O13 588.56

Recommended Compounds in Same Indication

Name CAS No Formula MW
LDK378 1032900-25-6 C28H36ClN5O3S 558.14
Pemetrexed (disodium) 150399-23-8 C20H19N5Na2O6 471.37
AZD1152 722543-31-9 C26H31FN7O6P 587.54
AZD1152-HQPA 722544-51-6 C26H30FN7O3 507.56
Mocetinostat 726169-73-9 C23H20N6O 396.44
Volasertib 755038-65-4 C34H50N8O3 618.81
ALK inhibitor 1 761436-81-1 C23H28BrN7O3S 562.48
Olaparib 763113-22-0 C24H23FN4O3 434.46
Afatinib (dimaleate) 850140-73-7 C32H33ClFN5O11 718.08
MGCD-265 analog 875337-44-3 C26H20FN5O2S2 517.5977
KX2-391 897016-82-9 C26H29N3O3 431.53
AT-101 90141-22-3 C30H30O8 518.55
MLN4924 905579-51-3 C21H25N5O4S 443.52
Tivantinib 905854-02-6 C23H19N3O2 369.42
IDO5L 914471-09-3 C9H7ClFN5O2 271.6356
Panobinostat 404950-80-7 C21H23N3O2 349.43
Tivozanib 475108-18-0 C22H19ClN4O5 454.86
Sunitinib 557795-19-4 C22H27FN4O2 398.47
Rigosertib 592542-59-1 C21H25NO8S 451.49
ON-019190 (sodium) 1225497-78-8 C21H24NNaO8S 473.4719
11

Route of Synthesis

12

References

13

More Information

Voreloxin

Tags: buy 175414-77-4 IC50 | 175414-77-4 price | 175414-77-4 cost | 175414-77-4 solubility | 175414-77-4 purchase | 175414-77-4 manufacturer | 175414-77-4 research buy | 175414-77-4 order | 175414-77-4 MSDS | 175414-77-4 chemical structure | 175414-77-4 Storage condition | 175414-77-4 molecular weight | 175414-77-4 mw | 175414-77-4 datasheet | 175414-77-4 supplier | 175414-77-4 cell line | 175414-77-4 NMR | 175414-77-4 MS | 175414-77-4 IR | 175414-77-4 solubility | 175414-77-4 Safe information | 175414-77-4 Qc and Spectral Information | 175414-77-4 Clinical Information | 175414-77-4 Clinical Trial | 175414-77-4 Route of Synthesis | 175414-77-4 storage condition | 175414-77-4 diseases and conditions | 175414-77-4 flash point | 175414-77-4 boiling point | 175414-77-4 melting point | 175414-77-4 storage condition | 175414-77-4 brand